Caplin Point Laboratories Ltd
NSE: CAPLIPOINT BSE: 524742
₹1690.10
(0.36%)
Sun, 15 Mar 2026, 03:17 am
Market Cap128.05B
PE Ratio21.00
Dividend0.36
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1987
- M/s Triwin Pharmaceuticals was started by Mr. P C Partheeban, Mr. T Palanisamy and Mr. S Karunakaran as a partnership firm
1990
- The Company was incorporated as CAPLIN POINT LABORATORIES PRIVATE LIMITED
- The Company was incorporated by the partners of M/s Triwin Pharmaceuticals alongwith Mr. B A Ahmed
1992
- M/s Triwin Pharmaceuticals started the Export of manufactured formulations
1993
- The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED
- The Company adopted a new set of Articles as applicable to public limited companies
- The Company took over M/s Triwin Pharmaceuticals with effect from 1st September
2010
- Caplin Point Laboratories Ltd recommended a final dividend of Re. 1/- per share
2011
- Caplin Point Laboratories Ltd recommended a final Dividend of Re. 1.50 per share
- Mr. Vivek Siddharth was appointed as the Chief Operating Officer of the Company
2012
- Caplin Point Laboratories Ltd recommended a final dividend of Rs. 2/- per share
- Mr. D. P. Mishra was appointed as a Whole Time Director of the Company
2013
- Mr. Mohanraj was appointed as the Vice President - Finance and Company Secretary of the company
2014
- Caplin commenced its additional line of Production in the area of Suppositories
- Caplin Point Lab was listed on Forbes Asia's '200 Best Billion' 2014
2015
- Caplin Point Lab received EU GMP approval for Sterile Injectable Site
- Caplin Point Lab received Brazil's Anvisa approval for Sterile Injectable Site
2016
- US FDA inspection was completed at Caplin Point's Injectable site
2017
- Caplin Point Laboratories received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ketorolac Tromethamine Injection 30mg/mL
- Caplin Point received USFDA nod for Ketorolac Tromethamine Injection
2018
- USFDA completed inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu
2019
- Caplin Point Laboratories partnered with Baxter Corporation for injectable portfolio
- USFDA completed inspection at Caplin Steriles Injectable site
- Caplin Steriles received USFDA nod for hemorrhage prevention drug
- Caplin Point Labs received an EIR from USFDA for injectable facility
2020
- Caplin Point Laboratories partnered with Xellia for injectable products
- Caplin Point Laboratories received final approval from the US drug regulator for its Abbreviated New Drug Application for Phenylephrine Hydrochloride injection
- Caplin Steriles received USFDA approval for Verapamil Hydrochloride Injection USP
2021
- Caplin Point arm inked a strategic partnership with Canada's JAMP Pharma Group
- Caplin Point Laboratories arm received USFDA nod for Neostigmine Methylsulfate Injection
2023
- Caplin Point Laboratories received the Lifetime Achievement Award 2023
- Caplin Point Laboratories received the Forbes Asia Best Under Billion Award 2023
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800